Global Genomics Group (G3) Announces Completion of Enrollment in GLOBAL Study with 7,500 Patients
May 27, 2014
RICHMOND, Va., May 27, 2014 /PRNewswire/ – Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease, today announced that i...
Global Genomics Group (“G3″) Appoints Harry “Chip” Davis, Zetia® Inventor, as Chief Drug Development Officer
May 6, 2014
RICHMOND, Va., May 6, 2014 /PRNewswire/ — Global Genomics Group (G3), a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnost...
Global Genomics Group (G3) and Caprion to Partner on GLOBAL Study to Identify Cardiovascular Disease Biomarkers and Drug Targets
February 26, 2014
RICHMOND, Va. and MONTREAL, Feb. 26, 2014 /PRNewswire/ — Global Genomics Group (G3) and Caprion Proteomics, Inc., today announced that they have entered into a collaboration agreement to investi...
Identification of Novel Cardiovascular Disease Pathways, Biomarkers
May 22, 2014
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States in both men and women of every major ethnic group. According to the American Heart Association (AHA), ...
The 3 Pillars to Understanding Cardiovascular Disease
May 14, 2014
The Doctor’s Channel: http://www.thedoctorschannel.com/view/the-3-pillars-to-understanding-cardiovascular-disease/...
Interview with Dr. Szilard Voros, CEO and Co-Founder of Global Genomics Group
February 27, 2014
Dr. Szilard Voros, CEO and co-founder of Global Genomics Group (G3), is currently heading the international GLOBAL study, which will enroll up to 10,000 patients with coronary artery disease. The coro...